Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
Vanderbilt University Medical Center · with National Heart, Lung, and Blood Institute (NHLBI) · NCT05375968
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 50
- US sites recruiting
- 1
- Study start
- February 25, 2023
- Record last updated
- December 5, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing. Across-sectional survey found that 25% of these patients complains that meals rich in carbohydrates are among the factors that further exacerbate POTS's symptoms and cause a myriad of gastrointestinal symptoms.
The splanchnic circulation is the largest blood volume reservoir of the human body, storing ≈25% of the total blood volume and contributing to sudden, and large, fluctuations in the stroke volume (SV). The orthostatic changes in systemic hemodynamics are particularly magnified after meals, due to increased blood volume sequestration triggered by the release of gastrointestinal peptides with vasodilatory properties. The purpose of this study is to determine if the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling on standing as compare to Healthy controls.
The study will also determine if glucose-induced GIP secretion increases splanchnic venous capacitance, orthostatic tachycardia and worsening POTS postprandial symptoms. For this purpose subjects will be further randomized to either saline versus GIP(3-30)NH2 acute infusion, to measure the changes their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hours.
Being studied: Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients; Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls; Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2; Compare change is SVC and SMA flow due to saline
Conditions: Postural Tachycardia Syndrome (POTS)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Between 18 and 50years of age
- Cases: Diagnosis of POTS with presyncope symptoms after meals Or
Controls
- With no significant past medical history, non-smokers and not on chronic medications.
- Body mass index (BMI) between 18.5 to 29.9 kg/m2
- If pre-menopausal women: must have regular menstrual cycle.
Exclusion Criteria
- BMI above ≥30 kg/m2
- Irregular menstrual cycle
- Intolerance to CPAP.
- Chronic use of acetaminophen
- Heart problems: myocardial infarction, angina, heart failure, stroke
- Undergone any heart related procedures or stents or on pacemaker.
- Uncontrolled hypertension.
- Type 1 or type 2 diabetes mellitus
- Pregnant or breast-feeding women.
- Impaired liver function
- Impaired Kidney function test.
- Anemia (Hematocrit\<34%).
- Ongoing substance abuse.
- Subjects with abnormal EKG
- History of seizures.
- Diagnosed with neuropathy due to any reason
- History of neck surgery.
- Smoker,
- On statin therapy for high cholesterol
- Rheumatoid arthritis.
- On oral corticosteroids,
- Current infections
- Documented of moderate decrease in blood volume
Recruiting US locations
Vanderbilt University Medical Center
Nashville, TN 37232
Site contact: Cyndya Shibao, MD, MSCI · cyndya.shibao@vumc.org
Study contacts (from the official record)
- Pedro J Ortiz, MD · 689-233-2623 · pedro.ortiz.saavedra@vumc.org
- Meena Golchha, MD · 615-322-3447 · meenakshi.golchha@vumc.org
Similar studies in Tennessee
All healthy volunteers studies in Tennessee →- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Cordova, TN + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
Sanofi
- Location
- Knoxville, TN + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Knoxville, TN + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
Xfibra, Inc.
- Location
- Knoxville, TN
- Eligibility basics
- Ages 18–55